Literature DB >> 1505701

Evaluating patients with chest pain using classification and regression trees.

F Buntinx1, J Truyen, P Embrechts, G Moreel, R Peeters.   

Abstract

We collected data on 320 patients complaining to their general practitioner of a new episode of chest pain, discomfort or oppression. Relationships were examined between initial signs and symptoms and a follow-up diagnosis after a period of 2 weeks to 2 months. The data were analysed with CART, a statistical decision theory software package. In our first run, the number of misclassifications by CART was 56%. After regrouping of the data and diagnostic categories, there were 37% misclassifications. The most discriminating variable turned out to be pain on palpation. When comparing each of five diagnostic groups to all others, we found a positive predictive value of 27% for gastrointestinal diseases, 72% for cardiovascular disorders, 69% for respiratory diseases, 58% for psychopathology and 73% for chest wall pathology. The CART methodology needs further investigation and testing before any clinical application will be possible in general practice.

Entities:  

Mesh:

Year:  1992        PMID: 1505701     DOI: 10.1093/fampra/9.2.149

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  9 in total

1.  Communicating accuracy of tests to general practitioners: a controlled study.

Authors:  Johann Steurer; Joachim E Fischer; Lucas M Bachmann; Michael Koller; Gerben ter Riet
Journal:  BMJ       Date:  2002-04-06

2.  Dealing with low-incidence serious diseases in general practice.

Authors:  Frank Buntinx; David Mant; Ann Van den Bruel; Norbert Donner-Banzhof; Geert-Jan Dinant
Journal:  Br J Gen Pract       Date:  2011-01       Impact factor: 5.386

3.  A Nationwide Flash-Mob Study for Suspected Acute Coronary Syndrome.

Authors:  Angel M R Schols; Robert T A Willemsen; Tobias N Bonten; Martijn H Rutten; Patricia M Stassen; Bas L J H Kietselaer; Geert-Jan Dinant; Jochen W L Cals
Journal:  Ann Fam Med       Date:  2019-07       Impact factor: 5.166

Review 4.  Signs and symptoms in diagnosing acute myocardial infarction and acute coronary syndrome: a diagnostic meta-analysis.

Authors:  Rudi Bruyninckx; Bert Aertgeerts; Pieter Bruyninckx; Frank Buntinx
Journal:  Br J Gen Pract       Date:  2008-02       Impact factor: 5.386

5.  Coronary heart disease in primary care: accuracy of medical history and physical findings in patients with chest pain--a study protocol for a systematic review with individual patient data.

Authors:  Jörg Haasenritter; Marc Aerts; Stefan Bösner; Frank Buntinx; Bernard Burnand; Lilli Herzig; J André Knottnerus; Girma Minalu; Staffan Nilsson; Walter Renier; Carol Sox; Harold Sox; Norbert Donner-Banzhoff
Journal:  BMC Fam Pract       Date:  2012-08-09       Impact factor: 2.497

6.  Excess of mortality in patients with chest pain peaks in the first 3 days period after the incident and normalizes after 1 month.

Authors:  Rudi Bruyninckx; Ann Van den Bruel; Frank Buntinx; Viviane Van Casteren; Bert Aertgeerts
Journal:  Fam Pract       Date:  2010-07-16       Impact factor: 2.267

7.  Chi-squared Automatic Interaction Detection Decision Tree Analysis of Risk Factors for Infant Anemia in Beijing, China.

Authors:  Fang Ye; Zhi-Hua Chen; Jie Chen; Fang Liu; Yong Zhang; Qin-Ying Fan; Lin Wang
Journal:  Chin Med J (Engl)       Date:  2016-05-20       Impact factor: 2.628

8.  Risk factors, time to onset and recurrence of delirium in a mixed medical-surgical ICU population: A secondary analysis using Cox and CHAID decision tree modeling.

Authors:  Farshid Rahimibashar; Andrew C Miller; Mahmood Salesi; Motahareh Bagheri; Amir Vahedian-Azimi; Sara Ashtari; Keivan Gohari Moghadam; Amirhossein Sahebkar
Journal:  EXCLI J       Date:  2022-01-04       Impact factor: 4.068

9.  GPs' reasons for referral of patients with chest pain: a qualitative study.

Authors:  Rudi Bruyninckx; Ann Van den Bruel; Karin Hannes; Frank Buntinx; Bert Aertgeerts
Journal:  BMC Fam Pract       Date:  2009-07-31       Impact factor: 2.497

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.